Published in Women's Health Weekly, May 15th, 2006
The article, titled "Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment," to be published in the Oncology Reports (2006;15-5:1299-1304), presents a case study from a U.S. National Cancer Institute (NCI)-sponsored phase 2 clinical trial of GTI-2040 in combination with capecitabine in metastatic breast cancer.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.